Replies to post #117609 on Biotech Values

[DewDiligence]

Biolex sells Locteron (a formulation of interferon for HCV) and its LEX production platform for an undisclosed sum:

http://www.marketwatch.com/story/biolex-sells-lex-system-to-synthon-and-initiates-sale-of-locteronr-2012-05-07

When investors thought interferon would remain a mainstay of HCV therapy for many years to come, Locteron was considered one of the most promising late-stage HCV programs.